Baxter International Inc.

Baxter Healthcare Sa

Baxalta Gmbh

Shawn F Bairstow

Kyungyoon Min

Sindhu Ramachandran

Hans-Peter Schwarz

Wolfgang Teschner

Richard J Johnson

Ruth Madlener

Jennifer Hutsell

Barrett E Rabinow

Sarah Elizabeth Lee

Jane Werling

Sharon Pokropinski

Mahesh V Chaubal

Barrett Rabinow

Francisco M Iii Rausa

Larry Backes

The present disclosure is directed to surface-modified particles and to methods of making and using the same. The surface-modified particles comprise a particle core and a coating associated with the particle core, wherein the particle core comprises an active agent, the coating comprises a surfactant having formula I, and the surface-modified particle has an average size from about 1 nm to about 2,000 nm: 

Compositions and methods for drug delivery

The present invention provides compositions and pharmaceutical formulations of IaIp derived from plasma. Also provided are methods for the manufacture of the IaIp compositions and formulations, as well as method for the treatment of diseases associated with IaIp dysfunction.

Manufacture of inter-alpha-inhibitor (IaIp) from plasma

The present invention provides compositions and pharmaceutical formulations of Factor H derived from plasma. Also provided are methods for the manufacture of the Factor H compositions and formulations, as well as methods for the treatment of diseases associated with Factor H dysfunction.

Manufacture of factor H (FH) and FH-derivatives from plasma

Methods and assays for oversulfated glycosaminoglycans are provided. In an embodiment, the present disclosure provides a method for detecting oversulfated glycosaminoglycan (OS-GAG) in a heparin sample. The method comprises placing the heparin sample onto a support comprising immobilized heparin and contacting the heparin sample on the support with a binding compound that attaches to the heparin and forms a heparin-binding compound complex. The binding compound also has a greater affinity for attaching to the OS-GAG than to the heparin in the heparin sample and forms an OS-GAG-binding compound complex. The method can further comprise detecting an amount of the heparin-binding compound complex on the support, and determining an amount of OS-GAG in the heparin sample based on the amount of the heparin-binding compound complex on the support.

Methods and assays for oversulfated glycosaminoglycans

Growing community of inventors

Gurnee, IL, United States of America

Shawn F Bairstow